MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Progressive supranuclear palsy(PSP)"

  • 2017 International Congress

    An evaluation of the diagnostic utility of radiological biomarkers in PSP

    J. Whitwell, G. Hoglinger, A. Antonini, Y. Bordelon, A. Boxer, C. Colosimo, R. Dodel, T. van Eimeren, L. Golbe, J. Kassubek, C. Kurz, I. Litvan, A. Pantelyat, G. Respondek, G. Rabinovici, J. Rowe, M. Stamelou, K. Josephs (Rochester, MN, USA)

    Objective: To critically evaluate the degree to which structural and molecular radiologic metrics fulfill criteria for diagnostic biomarkers of progressive supranuclear palsy (PSP). Background: PSP…
  • 2017 International Congress

    A PSP-like phenotype accompanies rapidly progressive dementia

    M. Dale, D. Erten-Lyons, F. Bittner, H.-Y. Jong, D. Bourdette, R. Woltjer (Charleston, SC, USA)

    Objective: We describe a patient with a progressive supranuclear palsy (PSP)-like phenotype and a rapidly progressive dementia, who was found to have an unknown CSF…
  • 2017 International Congress

    REM sleep behavior disorder: Is it useful to differentiate between Parkinson disease and Progressive Supranuclear Palsy?

    H. Gupta, S. Mehta, J. Hentz, H. Shill, E. Driver-Dunckley, M. Sabbagh, C. Belden, B. Dugger, T. Beach, G. Serrano, L. Sue, C. Adler (Scottsdale, AZ, USA)

    Objective: To determine the prevalence of rapid eye movement (REM) sleep behavior disorder (RBD) in autopsy confirmed Parkinson disease (PD) and Progressive Supranuclear Palsy (PSP).…
  • 2017 International Congress

    Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

    M. Jecmenica Lukic, T. Pekmezovic, I. Petrovic, A. Tomic, M. Svetel, V. Kostic (Belgrade, Serbia)

    Objective: The aim of this study was to determine the neuropsychiatric profile in our cohort of PSP patients and their dynamic changes over a follow-up…
  • 2017 International Congress

    Effect of low frequency stimulation on freezing of gait in a PSP patient with bilateral STN DBS

    T. Xie, M. Padmanaban (Chicago, IL, USA)

    Objective: To study the effect of low frequency stimulation (LFS) on freezing of gait (FOG) in a progressive supranuclear palsy (PSP) patient with bilateral STN…
  • 2017 International Congress

    Tyrosine kinase inhibition clears Tau and reserves neuropathology and motor symptoms in a novel model of progressive supranuclear palsy

    Y. Torres-Yaghi, F. Pagan, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, M. Javidnia, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Our objective was to examine the effects of tau accumulation in transgenic mice, observing both motor function and behavior.  Background: Tau hyper-phosphorylation is a…
  • 2017 International Congress

    Dysphagia in PSP

    H. Clark, J. Whitwell, J. Ahlskog, K. Josephs (Rochester, MN, USA)

    Objective: To characterize the nature of dysphagia accompanying progressive supranuclear palsy (PSP). Background: Dysphagia is a frequent symptom of PSP, typically occurring early in the…
  • 2017 International Congress

    Levodopa induced dyskinesia in a case of progressive supranuclear palsy.

    T. Yamamoto, H. Kawasaki, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, K. Takahashi, N. Tamura, N. Araki (Saitama, Japan)

    Objective: We describe the mechanism of dyskinesia in patients with progressive supranuclear palsy (PSP). Background: Levodopa generally shows a poor effect to parkinsonism in patients…
  • 2017 International Congress

    Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review

    G. Respondek, C. Kurz, T. Arzberger, E. Gelpi, D. Irwin, W. Meissner, A. Pantelyat, A. Rajput, J. Van Swieten, C. Troakes, K. Josephs, A. Lang, U. Mueller, C. Nilsson, Y. Bordelon, J.-C. Corvol, A. Boxer, L. Golbe, I. Litvan, M. Stamelou, G. Hoeglinger (Munich, Germany, Germany)

    Objective: To identify clinical features and investigations which predict PSP pathology during lifetime in the largest pathology PSP cohort reported to date compared to autopsy…
  • 2017 International Congress

    The phenotypic spectrum of patients with progressive supranuclear palsy

    M. Gultekin, R. Baydemir, M.F. Gol, M. Mirza (Kayseri, Turkey)

    Objective: The aim of the this study to evaluate different modes of (initial) clinic type of patients with PSP. Background: Progressive supranuclear palsy (PSP) is…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 38
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • An atypical and interesting feature of Parkinson´s disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley